The ARISE clinical trial is evaluating the safety and efficacy of an investigational drug to determine its effects on daytime sleepiness, tiredness, fatigue, and routine functioning in people with Idiopathic Hypersomnia and Narcolepsy without cataplexy.

For more information on this study please visit the website at: http://www.arisestudies.com/index.html

To enroll in this study at USF please contact Angela Aungst at (813)974-6378

The purpose of the clinical trial CHORDS is to evaluate the effectiveness and safety of the investigational drug Ocrelizumab in patients with relapsing remitting multiple sclerosis who have had a suboptimal response to an adequate course of disease-modifying treatments.

For more information on this study please visit the website at: http://www.gene.com/media/press-releases/14609/2015-10-08/genentechs-ocrelizumab-first-investigati

To enroll in this study at USF please contact Angela Aungst at (813)974-6378

This study is collecting information in safety and documenting the drug utilization of Tecfidera (Dimethyl Fumarate) when used in routine medical practice in the treatment of MS.

For more information on this study please visit the website at: https://clinicaltrials.gov/ct2/show/NCT02047097

To enroll in this study at USF please contact Angela Aungst at (813)974-6378

This clinical trial is a treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive MS.

For more information on this study please visit the website at: www.novartis.com/news/media-releases/novartis-announces-positive-phase-iii-results-showing-efficacy-baf312-patients

To enroll in this study at USF please contact Angela Aungst at (813)974-6378

This is a group study to evaluate the efficacy and safety of Ocrelizumab in comparison to interferon Beta-1A (Rebif) in patients with relapsing MS.

For more information on this study please visit the website at: https://clinicaltrials.gov/ct2/show/NCT01412333

To enroll in this study at USF please contact Angela Aungst at (813)974-6378

This is a long-term follow-up study for MS patients who have completed the alemtuzumab Extension Study (CAMMS03409).

For more information on this study please visit the website at: https://clinicaltrials.gov/ct2/show/NCT02167945 

To enroll in this study at USF please contact Angela Aungst at (813)974-6378

This is a phase IIIb, study to evaluate the effects of Orcelizumab on immune responses in patients with relapsing forms of MS.

To enroll in this study at USF please contact Angela Aungst at (813)974-6378

Open label study to evaluate safety and effectiveness of ocrelizumab in progressive forms of MS.  https://clinicaltrials.gov/ct2/show/NCT01412333

To enroll in this study at USF please contact Angela Aungst at (813)974-6378

Phase 2 study, to evaluate efficacy and safety of BIIB033 as add-on therapy to anti-disease-modifying therapies.  To evaluate the effects of BIIB033 versus placebo on disability improvement over 72 weeks and to evaluate the effects of BIIB033 versus placebo on additional measures of disability improvement.

For more information please visit the website at:  https://clinicaltrials.gov/ct2/show/NCT03222973

To enroll in this study at USF please contact Angela Aungst at (813)974-6378

Testing safety and efficacy of MD1003 in progressive multiple sclerosis.  The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the disability of patients suffering from progressive multiple sclerosis and especially those with gait impairment.

For more information please visit the website:  https://clinicaltrials.gov/ct2/show/NCT02936037 

To enroll in this study at USF please contact Angela Aungst at (813)974-6378

This randomized, parallel group, double-blind, placebo controlled study will evaluate the efficacy and safety of ocrelizumab in participants with primary progressive multiple sclerosis. Eligible participants will be randomized 2 : 1 to receive either ocrelizumab or placebo. The blinded treatment period will be at least 120 weeks, followed by an Open Label Extension (OLE) treatment for participants in both groups who in the opinion of the investigator could benefit from further or newly initiated ocrelizumab treatment. Unless terminated early, all participants will continue their treatment with open-label ocrelizumab until the last participant who entered the OLE phase reaches 4 years of open-label ocrelizumab treatment.

For more information please visit the website at:  https://clinicaltrials.gov/ct2/show/NCT01194570 

To enroll in this study at USF please contact Angela Aungst at (813)974-6378

Double masked, placebo controlled study with open label period to evaluate and compare the efficacy of MEDI-551 versus placebo in reducing the risk of an NMO/NMOSD attack in subjects with NMO/NMOSD.

For more information please visit the website at:  https://clinicaltrials.gov/ct2/show/NCT02200770 

To enroll in this study at USF please contact Angela Aungst at (813)974-6378

Double blind, placebo controlled study to assess efficacy and safety of HP Acthar gel in RRMS.

To enroll in this study at USF please contact Angela Aungst at (813)974-6378

Prospective, post authorization safety study to evaluate long term safety profile of Lemtrada 

To enroll in this study at USF please contact Angela Aungst at (813)974-6378

Study for RRMS/PPMS patients switching therapy, to assess relationship between cognitive function and brain atrophy.

To enroll in this study at USF please contact Angela Aungst at (813)974-6378

Phase 3, study of treatment effects of ublituximab in MS.

To enroll in this study at USF please contact Angela Aungst at (813)974-6378